The dopamine D-4 receptor has been investigated for its potential role in several CNS disorders, notably schizophrenia and more recently, erectile dysfunction. Whereas studies have investigated dopamine D-4 receptor- mediated signaling in vitro, there have been few, if any, attempts to identify dopamine D-4 receptor signal transduction pathways in vivo. In the present studies, the selective dopamine D-4 agonist PD168077 induces c-Fos expression and extracellular signal regulated kinase (ERK) phosphorylation in the hypothalamic paraventricular nucleus (PVN), a site known to regulate proerectile activity. The selective dopamine D-4 receptor antagonist A-381393 blocked both c-Fos expression and ERK1/2 phosphorylation produced by PD168077. In addition, PD168077-induced ERK1/2 phosphorylation was prevented by SL327, an inhibitor of ERK1/2 phosphorylation. Interestingly, treatment with A-381393 alone significantly reduced the amount of Fos immunoreactivity as compared to basal expression observed in vehicle-treated controls. Dopamine D-4 receptor and c-Fos coexpression in the PVN was observed using double immunohistochemical labeling, suggesting that PD168077-induced signaling may result from direct dopamine D-4 receptor activation. Our results demonstrate functional dopamine D-4 receptor expression and natural coupling in the PVN linked to signal transduction pathways that include immediate early gene and MAP kinase activation. Further, the ability of the selective dopamine D-4 antagonist A-381393 alone to reduce c-Fos expression below control levels may imply the presence of a tonic dopamine D-4 receptor activation under basal conditions in vivo. These findings provide additional evidence that the PVN may be a site of dopamine D-4 receptor- mediated proerectile activity. (c) 2005 Elsevier Ltd. All rights reserved.